造血干细胞移植治疗重型再生障碍性贫血的研究进展

Research Progress on Hematopoietic Stem Cell Transplantation in the Treatment of Severe Aplastic Anemia

异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation, allo-HSCT)是治疗重型再生障碍性贫血(severe aplastic anemia, SAA)最有效的方法之一。随着近年来异基因造血干细胞移植临床实践的规范化和单倍体相合造血干细胞移植的进展,异基因造血干细胞移植已经迎来了新时代。基于国内和国际的前沿发展,探讨当前医疗背景下SAA患者allo-HSCT的适应症、供者选择、预处理方案以及移植物抗宿主病的预防措施等移植程序对于SAA患者移植预后至关重要,本文将围绕以上SAA相关移植程序的应用进展做一综述。

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered a highly effective treatment method. Recent advancements in haploidentical hematopoietic stem cell transplantation, along with the standardization of clinical practices for allo-HSCT, have marked a new era in the field. It is essential to explore indications, donor selection, conditioning regimens, preventive measures for graft-versus-host disease and other transplantation procedures in SAA patients. These factors significantly impact the transplant prognosis for SAA patients. This article will provide a comprehensive review of the progress in SAA-related transplantation procedures, drawing on cutting-edge developments both in China and abroad.